arrow_back Back to App

Protecting Health Institute Directors: Ensuring Medical Research Stability

This act aims to ensure stability in the management of key health research institutes. It stipulates that directors of these facilities can only be removed under specific circumstances, which is intended to support long-term research projects and medical advancements. Citizens can expect important disease research to be conducted more continuously and independently of political changes.
Key points
Directors of national health research institutes can only be removed for serious misconduct, neglect of duty, or incapacity.
This change aims to protect the independence and continuity of scientific research in public health.
It introduces greater stability in the management of key medical facilities, which may lead to more effective research and development of new therapies.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_2002
Sponsor: Sen. Markey, Edward J. [D-MA]
Process start date: 2021-06-10
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

National Institutes of Health Director Protection Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_2002.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-06-10.

What are the main provisions?

Key points include:

  • Directors of national health research institutes can only be removed for serious misconduct, neglect of duty, or incapacity.
  • This change aims to protect the independence and continuity of scientific research in public health.
  • It introduces greater stability in the management of key medical facilities, which may lead to more effective research and development of new therapies.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Markey, Edward J. [D-MA].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Health